Publication

Witte MH, Dellinger MT, Papendieck CM, Boccardo F. 2012. Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia. Clin Exp Metastasis. 29:707–27. doi:10.1007/s10585-012-9493-1.

Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS. 2012. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs. 21:1247–66. doi:10.1517/13543784.2012.703177.

Beamer PI, Luik CE, Abrell L, Campos S, Martinez ME, Sáez AE. 2012. Concentration of trichloroethylene in breast milk and household water from Nogales, Arizona. Environ Sci Technol. 46:9055–61. doi:10.1021/es301380d.

Pu JJ, Hu R, Mukhina GL, Carraway HE, McDevitt MA, Brodsky RA. 2012. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica. 97:1225–33. doi:10.3324/haematol.2011.048215.

Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, et al. 2012. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature. 487:491–5. doi:10.1038/nature11288.

Bardach SH, Schoenberg NE, Fleming ST, Hatcher J. 2012. Relationship between colorectal cancer screening adherence and knowledge among vulnerable rural residents of Appalachian Kentucky. Cancer Nurs. 35:288–94. doi:10.1097/NCC.0b013e31822e7859.

Studts CR, Tarasenko YN, Schoenberg NE, Shelton BJ, Hatcher-Keller J, Dignan MB. 2012. A community-based randomized trial of a faith-placed intervention to reduce cervical cancer burden in Appalachia. Prev Med. 54:408–14. doi:10.1016/j.ypmed.2012.03.019.

Patel SH, Robbins JR, Gore EM, Bradley JD, Gaspar LE, Germano I, Ghafoori P, Henderson MA, Lutz ST, McDermott MW, et al. 2012. ACR Appropriateness Criteria® follow-up and retreatment of brain metastases. Am J Clin Oncol. 35:302–6. doi:10.1097/COC.0b013e31824be246.

Renquist BJ, Murphy JG, Larson EA, Olsen D, Klein RF, Ellacott KLJ, Cone RD. 2012. Melanocortin-3 receptor regulates the normal fasting response. Proc Natl Acad Sci U S A. 109:E1489–98. doi:10.1073/pnas.1201994109.

Stern JH, Kim K, Ramsey JJ. 2012. The influence of acute, late-life calorie restriction on whole body energy metabolism in p66Shc(-/-) mice. Mech Ageing Dev. 133:414–20. doi:10.1016/j.mad.2012.05.001.

Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC, Woodford R-MT, Davis BK, Uronis JM, Herfarth HH, et al. 2012. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity. 36:742–54. doi:10.1016/j.immuni.2012.03.012.

Chambers SK, Chow H-HS, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, et al. 2012. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin Cancer Res. 18:2668–78. doi:10.1158/1078-0432.CCR-12-0261.

Bhattacharya MRC, Gerdts J, Naylor SA, Royse EX, Ebstein SY, Sasaki Y, Milbrandt J, DiAntonio A. 2012. A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration. J Neurosci. 32:5054–61. doi:10.1523/JNEUROSCI.4951-11.2012.

Morrison CM, Dial SM, Day WA, Joens LA. 2012. Investigations of Salmonella enterica serovar newport infections of oysters by using immunohistochemistry and knockout mutagenesis. Appl Environ Microbiol. 78:2867–73. doi:10.1128/AEM.07456-11.

Duan J, Mansour HM, Zhang Y, Deng X, Chen Y, Wang J, Pan Y, Zhao J. 2012. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 426:193–201. doi:10.1016/j.ijpharm.2012.01.020.

Byron SA, Min E, Thal TS, Tapia C, Hostetter G, Watanabe A, Azorsa D, Little TH and Kim S. (2012) Attenuation of NF-kappa B by the ING4 tumor suppressor in breast cancer. PLoS One 7(10):e46823. 2012.

Rausch MP, Hastings KT. 2012. GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1. J Invest Dermatol. 132:154–62. doi:10.1038/jid.2011.236.

Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich JL, Gnerlich J, Darga TE, et al. 2012. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 7:e50141. doi:10.1371/journal.pone.0050141.

Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, Caulin C. 2011. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol. 225:479–89. doi:10.1002/path.2971.

Bolger TA, Wente SR. 2011. Gle1 is a multifunctional DEAD-box protein regulator that modulates Ded1 in translation initiation. J Biol Chem. 286:39750–9. doi:10.1074/jbc.M111.299321.

Ahluwalia MS, Patel M, Peereboom DM. 2011. Role of tyrosine kinase inhibitors in the management of high-grade gliomas. Expert Rev Anticancer Ther. 11:1739–48. doi:10.1586/era.11.166.

Ooi A, Wong J-C, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BWH, Tan M-H, Zhang Z, Yang XJ, et al. 2011. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 20:511–23. doi:10.1016/j.ccr.2011.08.024.

Brabez N, Lynch RM, Xu L, Gillies RJ, Chassaing G, Lavielle S, Hruby VJ. 2011. Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment. J Med Chem. 54:7375–84. doi:10.1021/jm2009937.

Sukhtankar D, Okun A, Chandramouli A, Nelson MA, Vanderah TW, Cress AE, Porreca F, King T. 2011. Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Mol Pain. 7:81. doi:10.1186/1744-8069-7-81.

Sheeran PS, Luois S, Dayton PA, Matsunaga TO. 2011. Formulation and acoustic studies of a new phase-shift agent for diagnostic and therapeutic ultrasound. Langmuir. 27:10412–20. doi:10.1021/la2013705.